Malta - English - Medicines Authority

ever valinject gmbh oberburgau 3 4866 unterach am attersee , austria - solution for injection in a pre-filled syringe - fulvestrant 250 ml/5ml - endocrine therapy

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis uk limited - fulvestrant - solution for injection in pre-filled syringe - 250mg millilitre - anti-estrogens

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sudair pharma company, saudi arabia - fulvestrant - solution for injection - 50 mg/ml

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

reddy holding gmbh - fulvestrant 250 mg - solution for injection in pre-filled syringe - fulvestrant

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eugia pharma (malta) ltd. - fulvestrant 250 mg - solution for injection in pre-filled syringe - fulvestrant

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية الصباغ - sabbagh drug store - fulvestrant 250 mg/5ml - 250 mg/5ml

Australia - English - Department of Health (Therapeutic Goods Administration)

eugia pharma (australia) pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: benzyl alcohol; benzyl benzoate; ethanol; castor oil - fulvestrant epsl is indicated for the treatment of postmenopausal women with:,? hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy.,? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

eugia pharma (australia) pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: benzyl alcohol; ethanol; benzyl benzoate; castor oil - fulvestrant eugia is indicated for the treatment of postmenopausal women with:,? hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy.,? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dr. reddy`s laboratories malaysia sdn. bhd. - fulvestrant -

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - fulvestrant 50 mg/ml - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml excipient: benzyl alcohol benzyl benzoate castor oil ethanol - indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age, previously treated with endocrine therapy (antioestrogen or aromatase inhibitor therapy), irrespective of whether their postmenopausal status occurred naturally or was artificially induced.